Candel Therapeutics, Inc. Common Stock (CADL) Stock Price
CADLStock
$8.19+51.11%52W
Market Cap$626.69M
P/E—
PEG Ratio—
Div yield—
Beta-0.26
CADL Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)50.68%
Price vs S&P 500 (4W)-25.62%
VGM Score37.41
CADL Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.23 | -$0.36 | -52.85%(-$0.12) | |
| Q1 2026 | -$0.33 | -$0.14 | +57.06%(+$0.19) | |
| Q4 2025 | -$0.23 | -$0.29 | -23.83%(-$0.06) | |
| Q3 2025 | -$0.17 | -$0.23 | -37.09%(-$0.06) | |
| Q2 2025 | -$0.17 | -$0.20 | -16.57%(-$0.03) |
CADL Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.13
4.07
4.13
4.13
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
CADLCandel Therapeutics, Inc. Common Stock | F | — | B | 5053.9x | — | — | — | $8.19 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Candel Therapeutics, Inc. Common Stock
Candel Therapeutics is a clinical-stage biopharmaceutical company developing viral immunotherapies designed to activate immune responses against cancer. The company operates two proprietary viral platforms based on genetically modified adenovirus and herpes simplex virus (HSV) constructs, positioning it in the emerging viral oncology sector.